DelveInsight’s ‘High-Grade Glioma Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline High-Grade Glioma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the High-Grade Glioma pipeline domain.

For High-Grade Glioma emerging drugs, the High-Grade Glioma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

To know more about the report offerings, click here @ High-Grade Glioma Pipeline

 

Key Takeaways from the High-Grade Glioma Pipeline Report

• DelveInsight’s High-Grade Glioma Pipeline analysis depicts a robust space with 150+ active players working to develop 150+ pipeline therapies for High-Grade Glioma treatment. 
• The leading High-Grade Glioma companies include Mateon Therapeutics, BioMimetix, Oblato, Inc, PTC Therapeutics, Lee’s Pharmaceutical Limited, Nuvation Bio, Inc., Laminar Pharmaceuticals, Basilea Pharmaceutica, Aadi, LLC, Erimos Pharmaceuticals, Istari Oncology, Angiochem, Epitopoietic Research Corporation, Oblato, Inc., Novartis, Candel Therapeutics, Chimerix, Onxeo SA, SonALAsense, Kintara Therapeutics, Kazia Therapeutics, VBI Vaccines, Lantern Pharma, NeOnc Technologies, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals, Cellectar Biosciences, OncoSynergy, Inc, WPD Pharmaceuticals, CellabMED, Alpheus Medical, Inc., Eli Lilly and Company, Xynomic Pharmaceuticals, Inc., Celldex Therapeutics, Sumitomo Pharma Oncology, Inc., Curis, Plus Therapeutics, and others are evaluating their lead assets to improve the High-Grade Glioma treatment landscape.
• Key High-Grade Glioma pipeline therapies in various stages of development include OT101, BMX-001, OKN-007, PTC596, TG02, NUV-422, 2-OHOA, BAL101553, ABI-009, Terameprocol, Anlotinib hydrochloride, PVSRIPO, ANG1005, ERC1671, OKN-007, dabrafenib, LAM561, ONC-201, AsiDNA, SONALA-001, VAL-083, Paxalisib, VBI-1901, STAR-001, NEO100, MK-3475, cemiplimab, CLR 131, OS2966, Berubicin Hydrochloride, YYB-103, 5 Aminolevulinic Acid, LY2157299, PCI 24781, IMA950, DSP-0390, Fimepinostat, and others.
• In February 2023, Plus Therapeutics reported that the company is Engaged with the FDA on proposed Investigational New Drug (IND) application to treat pediatric patients with ependymoma and high-grade glioma.
• In January 2023, IN8bio, Inc., a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced a clinical update from the ongoing Phase I trial evaluating INB-200 in patients with newly diagnosed GBM and provided pipeline goals for 2023. All three patients exceeded the median progression-free survival (PFS) of seven months with two ongoing responses extending beyond 1.5 years and 1.2 years progression-free, respectively, in initial data from Cohort 2 of the Phase 1 INB-200 trial in newly diagnosed glioblastoma multiforme (GBM). The company plans to complete enrollment of Cohort 3 in the Phase I trial and also to report additional data and topline results with longer-term follow-up.

 

Request a sample and discover the recent breakthroughs happening in the High-Grade Glioma pipeline landscape @ High-Grade Glioma Pipeline Outlook

 

High-Grade Glioma Overview

High-grade glioma is a formidable and aggressive form of brain tumor that originates in the glial cells of the central nervous system. These tumors are known for their rapid growth and invasive nature, making them particularly challenging to treat. The exact causes of high-grade gliomas remain elusive, though some genetic factors and exposure to ionizing radiation have been implicated as potential contributors.

Symptoms of high-grade gliomas can vary depending on their location within the brain. Common signs include persistent headaches, seizures, changes in personality or behavior, and neurological deficits such as weakness, numbness, or difficulty with coordination. As these tumors grow, they can exert pressure on surrounding brain tissue, leading to a wide range of neurological symptoms.

Diagnosing high-grade gliomas typically involves a combination of imaging studies like MRI or CT scans, along with a biopsy to confirm the tumor’s grade and type. Molecular profiling of the tumor may also help guide treatment decisions.

Treatment for high-grade gliomas is complex and often involves a multidisciplinary approach. Surgery is usually the first step to remove as much of the tumor as possible, followed by radiation therapy and chemotherapy. Targeted therapies and immunotherapies are also being explored as promising treatment options.

 

Find out more about High-Grade Glioma medication @ New Drug for High-Grade Glioma 

 

High-Grade Glioma Treatment Analysis: Drug Profile

OT101: Mateon Therapeutics

OT101, a first-in-class RNA therapy, is intended to reverse TGF-beta 2’s immunosuppressive effects. OT-101 demonstrated clinically substantial single-agent action and generated permanent complete and partial responses in recurrent and refractory adult High-Grade Glioma patients, including adults with GBM, in a completed Phase II clinical research. Further development of OT-101 may provide renewed hope for children DIPG patients suffering from this rare and devastating condition.

 

PTC596: PTC Therapeutics

PTC596 is an orally active small molecule that reduces the function, activity, and quantity of BMI1 in tumor stem cell populations. PTC596 works by modifying and eliminating the BMI1 protein via a process known as phosphorylation. PTC596 effectively suppressed BMI1 function in a variety of tumor cell lines. PTC596 primarily targeted chemotherapy-resistant cancer stem cells in in vitro experiments. In tests with tumor cell lines from fibrosarcoma, prostate, and colon malignancies, PTC596 preferentially reduced cancer stem cells. The cytotoxic chemotherapies carboplatin, temozolomide, methotrexate, and indibulin, on the other hand, enhanced the population of cancer stem cells in this experiment. It is currently in the development phase I.

 

Key High-Grade Glioma Therapies and Companies

• ONC201: Chimerix
• BMX-001: BioMimetix
• OKN-007: Oblato, Inc.
• Lisavanbulin: Basilea Pharmaceutica
• Terameprocol: Erimos Pharmaceuticals
• Zotiraciclib: Adastra Pharmaceuticals/S*Bio
• PTC596: PTC Therapeutics
• CAN-3110: Candel Therapeutics
• OS2966: OncoSynergy

 

Learn more about the novel and emerging High-Grade Glioma pipeline therapies @ High-Grade Glioma Clinical Trials

 

High-Grade Glioma Therapeutics Assessment

By Product Type

• Monotherapy
• Combination Therapy

By Stage

• Discovery
• Pre-Clinical
• Phase I
• Phase II
• Phase III
• Pre-registration

By Route of Administration

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravenous
• Oral
• Parenteral
• Subcutaneous

By Molecule Type

• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies

 

Scope of the High-Grade Glioma Pipeline Report 

• Coverage: Global 
• Key High-Grade Glioma Companies: Mateon Therapeutics, BioMimetix, Oblato, Inc, PTC Therapeutics, Lee’s Pharmaceutical Limited, Nuvation Bio, Inc., Laminar Pharmaceuticals, Basilea Pharmaceutica, Aadi, LLC, Erimos Pharmaceuticals, Istari Oncology, Angiochem, Epitopoietic Research Corporation, Oblato, Inc., Novartis, Candel Therapeutics, Chimerix, Onxeo SA, SonALAsense, Kintara Therapeutics, Kazia Therapeutics, VBI Vaccines, Lantern Pharma, NeOnc Technologies, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals, Cellectar Biosciences, OncoSynergy, Inc, WPD Pharmaceuticals, CellabMED, Alpheus Medical, Inc., Eli Lilly and Company, Xynomic Pharmaceuticals, Inc., Celldex Therapeutics, Sumitomo Pharma Oncology, Inc., Curis, Plus Therapeutics, and others.
• Key High-Grade Glioma Pipeline Therapies: OT101, BMX-001, OKN-007, PTC596, TG02, NUV-422, 2-OHOA, BAL101553, ABI-009, Terameprocol, Anlotinib hydrochloride, PVSRIPO, ANG1005, ERC1671, OKN-007, dabrafenib, LAM561, ONC-201, AsiDNA, SONALA-001, VAL-083, Paxalisib, VBI-1901, STAR-001, NEO100, MK-3475, cemiplimab, CLR 131, OS2966, Berubicin Hydrochloride, YYB-103, 5 Aminolevulinic Acid, LY2157299, PCI 24781, IMA950, DSP-0390, Fimepinostat, and others.

 

Dive deep into rich insights for drugs used for High-Grade Glioma treatment; visit @ High-Grade Glioma Drugs 

 

Table of Contents

1.	Introduction
2.	Executive Summary
3.	High-Grade Glioma Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	High-Grade Glioma Pipeline Therapeutics
6.	High-Grade Glioma Pipeline: Late Stage Products (Phase III)
7.	High-Grade Glioma Pipeline: Late Stage Products (Phase III)
8.	High-Grade Glioma Pipeline: Mid-Stage Products (Phase II)
9.	High-Grade Glioma Pipeline: Early Stage Products (Phase  I)
10.	Therapeutic Assessment
11.	Inactive Products
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

 

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting